Abbott实验室比预期的收入高,但损失了收入,价值2 284.6亿美元,评级为“Moderate Buy”。 Abbott Labs beat earnings expectations but missed revenue, valued at $228.46 billion with a "Moderate Buy" rating.

Abbott实验室报告一个强劲的季度,超过EPS的预期值,为1.09美元,尽管收入略低于103.6亿美元。 Abbott Laboratories reported a strong quarter, exceeding EPS expectations with $1.09, though revenue slightly missed at $10.36 billion. 一些机构增加了其股份,其中包括Azzad资产管理公司,该公司现在拥有38 597份股份。 Several institutions increased their holdings, including Azzad Asset Management, which now owns 38,597 shares. 股票的评级为"中等买入",目标价142.59美元. The stock has a "Moderate Buy" rating and a $142.59 price target. Abbott经营保健产品,市场上限为228.46亿美元。 Abbott operates in healthcare products with a market cap of $228.46 billion.